Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity

Keyphrases

• A1 Receptor 100%
• Receptor Agonist 100%
• Glucagon-like 100%
• Obesity Treatment 100%
• Clinical Development 60%
• Obesity 60%
• Agonism 60%
• Semaglutide 60%
• Quality of Life 20%
• Type 2 Diabetes Mellitus (T2DM) 20%
• Increasing Risk 20%
• Energy Balance 20%
• Energy Metabolism 20%
• Public Health 20%
• Expert Opinion 20%
• Anti-obesity 20%
• Area Cover 20%
• If Current 20%
• Glucagon 20%
• Amylin 20%
• Inhibitory Peptide 20%
• Oxyntomodulin 20%
• Living with Diabetes 20%
• Hormonal System 20%
• Cotadutide 20%
• Cagrilintide 20%
• Tirzepatide 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Glucagon Like Peptide 1 Receptor Agonist 100%
• Glucagon-Like Peptide 1 Receptor 100%
• Semaglutide 100%
• Disease 33%
• Non Insulin Dependent Diabetes Mellitus 33%
• Glucagon 33%
• Glucagon-Like Peptide-1 33%
• Amylin 33%
• Oxyntomodulin 33%
• Efinopegdutide 33%
• Pegapamodutide 33%
• Tirzepatide 33%